Endo Inc.

OTCPK:ENDP.Q Stock Report

Market Cap: US$141.1k

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Endo International Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Endo International.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth23.9%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Endo creditors looking at putting company up for sale through bankruptcy - Bloomberg

Aug 16

Endo International sees 23% rise on 3x higher than normal volume

Aug 03

Endo outperforms defying bankruptcy fears and generic entry

Jul 25

Endo weighs bankruptcy filing without opioid settlement - WSJ

Jul 12

Endo International cools off, giving back some of its 85% Tuesday gain

Jun 29

Endo: Stick A Fork In It

May 10

Endo: About As Bad As It Gets

Mar 07

Endo: FDA Approves Generic Form Of Vasostrict Creating Headwind Into Next Year

Dec 16

Endo: A Win In California But Equity Value Still A Question

Nov 02

Endo International: Loses Vasostrict Trial

Aug 31

Endo International: Hires Restructuring Advisor

Aug 20

Endo International: All About Ongoing Litigation

Aug 07

Endo: Appellate Court Denies Request To Postpone Damages Trial Might Be End O' The Road

Jul 15

Endo International: Bankruptcy Seems Like The Only Practical Option

Jun 30

Endo International wins FDA approval for Micafungin new formulation

Jun 17

Endo International plc 2021 Q1 - Results - Earnings Call Presentation

May 07

Radius Health partners with Endo unit for abaloparatide in Canada

Jan 05

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Endo International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

OTCPK:ENDP.Q - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20232,012-2,448341435N/A
9/30/20232,070-252334430N/A
6/30/20232,160-942285391N/A
3/31/20232,182-2,84721130N/A
12/31/20222,319-2,910166269N/A
9/30/20222,552-3,22111110N/A
6/30/20222,783-2,552-980N/A
3/31/20222,928-681277369N/A
12/31/20212,993-569326411N/A
9/30/20212,964129484569N/A
6/30/20212,827109345429N/A
3/31/20212,801137506579N/A
12/31/20202,903247327402N/A
9/30/20202,908-102195268N/A
6/30/20203,002-75299378N/A
3/31/20203,014-190180251N/A
12/31/20192,914-3613098N/A
9/30/20192,936-418108190N/A
6/30/20192,952-52263135N/A
3/31/20192,967-47747128N/A
12/31/20182,947-962177267N/A
9/30/20182,929-968238329N/A
6/30/20182,971-921324434N/A
3/31/20183,132-1,565311435N/A
12/31/20173,469-1,233428554N/A
9/30/20173,942-4,294N/A507N/A
6/30/20174,039-4,386N/A309N/A
3/31/20174,084-3,300N/A742N/A
12/31/20164,010-3,224N/A528N/A
9/30/20163,842553N/A683N/A
6/30/20163,704-59N/A698N/A
3/31/20163,518-539N/A106N/A
12/31/20153,269-300N/A119N/A
9/30/20152,858-725N/A-75N/A
6/30/20152,766128N/A310N/A
3/31/20152,624260N/A492N/A
12/31/20142,38158N/A338N/A
9/30/20142,303-643N/A277N/A
6/30/20142,310-637N/A141N/A
3/31/20142,429-650N/A124N/A
12/31/20132,125189N/A299N/A
9/30/20132,621-628N/A711N/A
6/30/20132,711-629N/A683N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ENDP.Q's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if ENDP.Q's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ENDP.Q's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ENDP.Q's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ENDP.Q's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ENDP.Q's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/02 05:02
End of Day Share Price 2024/05/02 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Endo Inc. is covered by 44 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard SilverBarclays
Gary NachmanBMO Capital Markets Equity Research
Sumant Satchidanand KulkarniBofA Global Research